Today Stories

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany. Telix today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (Merck), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019. TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. Under t…

Thermo Fisher Scientific, the world leader in serving science, and ChromSword, a provider of innovative software products, have collaborated to launch an automated high performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) method development system that enables chromatographers to deliver robust and validated methods in less time and with higher confidence. The new Thermo Scientific Vanquish Method Development HPLC and UHPLC system provides an integrated, network-deployable solution for automated method development and validation for diode-array, charged aerosol and mass spectrometric detection. Built for ease-of-use and speed, the system strategically combines the leading Vanquish HPLC and UHPLC systems and the Thermo Scientific Chromeleon Chrom…

Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota Majority of participants who received primary series maintain detectable binding and functional antibodies against variants for 6 months Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the publication of new data on the durability of the Moderna COVID-19 vaccine in generating neutralizing antibodies against variants of concern. The manuscript was published in Science. According to the paper, the majority of individuals vaccinated with the Moderna COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose. “We are pleased with these new data showing that people vaccinat…

Medicines Discovery Catapult (MDC) and We Share Ventures have embarked on a joint venture, piloting an innovative funding model aimed at opening new funding opportunities for early-stage medicines discovery. For too long, accessing catalytic funding has been a challenge for medicines discovery start-ups focused on areas of clinical unmet need. This impact-driven revolving funding model is the first of its kind in the sector and has the potential to create and sustain funding opportunities for medicines discovery start-ups focused on patient impact. The pilot brings together We Share’s innovative impact-driven revolving funding model with MDC Syndicate’s programme, enabling promising start-ups in the medicine discovery space access to long-term capital in the early phases of their growth. T…

Manufacturing facility to provide access to domestically manufactured vaccines against respiratory viruses Collaboration will support Canada with direct access to rapid pandemic response capabilities First instance of sustainable national business model that Company expects to apply to other geographies Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine. The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to M…

Vancouver, Canada. August 9, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease. “We are very happy to be collaborating with Massachusetts General Hospital and Dr. Kastanenka to study the mechanism of our technology in an Alzheimer’s disease model,” stated Dr. Daniel Mikol, NervGen’s Chief Medical Officer. “As the original and largest teaching hospital for Harvard University, and one of the largest funded…

– Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio – – Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China – – HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details – Hong Kong, Shanghai, Florham Park, N.J. and Cambridge, Mass—Monday, August 9, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company dev…

Galt Pharmaceuticals®, a pharmaceutical company committed to enhancing the quality of life of patients with products that meet unmet clinical needs, has introduced a 4-day work week for its employees. In a LinkedIn post, CEO and Co-Founder Barry Patel said, “We are not big pharma and are actually looking to disrupt the inefficient big pharma model. We know we can’t always offer the big pharma perks, but we can offer work-life balance and a family-first culture.” About Galt Pharmaceuticals® Galt Pharmaceuticals® has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve. Galt is the first and only company to cr…

- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence - The new intuitive interface provides step-by-step guidance to enhance ease of use - When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow…

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully dilute…

BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier Heidelberg, 02.08.2021. German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The start of these projects represents a major milestone in the strategic partners’ successful collaboration and addresses two challenging new research areas. Both collaborations were facilitated by Johnson & Johnson Innovation. The new research group PTA (‘Pro…

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. Through the multi-year collaboration, Kumquat will utilize its small molecule immuno-oncology (IO) platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China. Kumquat has retained development and commercialization rights in Greater China for each of the drug candidates selected by Lilly, subject to Lilly's option to co-commercialize in Greater China. Ad…

Collaboration seeks to obtain direct insights from patients to improve clinical trial accessibility, drive efficiency  Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced an innovative partnership with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to develop patient-centric protocol designs and methodologies for decentralized clinical trials in China. The collaboration will also include quantitative research to improve the clinical trial experience of oncology patients. “We are honored to be partnering with CHCAMS,” said Vicky Hsu, Corporate Vice President, Greater China Region Head and Head of Asia/Pacific Biotech Operations for Parexel. “The Cancer Hospital…

28 July 2021 - Today, WHO joins the global community in celebrating World Hepatitis Day with the theme “Hepatitis can’t wait”, calling on all countries to work together to eliminate viral hepatitis as a public health threat by 2030. A hepatitis-free future is achievable with a united effort. Over 354 million people worldwide live with chronic hepatitis; over 8000 new infections of hepatitis B and C occur every day, and more than one million deaths from advanced liver disease and liver cancer occur every year. The 2021 Global report on HIV, viral hepatitis and sexually transmitted infections, took stock of the progress achieved in the last 5 years, the setbacks caused by the pandemic, and the lessons learned for the coming decade.  Although the extent of progress in the hepatitis response h…

Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, and Glycotope, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, have entered into a platform access agreement to discover and develop antibodies that target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets). Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclosed. “Selective tumor targeting is key to maximize the potential of our linker-drug platfo…

Translational Science Center for the Healthcare business sector to offer flexible ways of working coupled with the latest technology and equipment New Learning Center will bring all vocational training occupations together under one roof Both construction projects meet the highest sustainability requirements Merck, a leading science and technology company, plans to invest € 270 million at its global headquarters in Darmstadt by building a new Translational Science Center for its Healthcare business sector as well as a new Learning Center. The two construction projects are part of the € 1 billion investment package that Merck announced in March 2019 and plans to realize in Darmstadt by 2025. “Darmstadt is our site of the future. With these investments, we are underscoring the strategic im…

Bachem is pleased to announce that the company has been recognised as one of the five winners of the Swiss Biotech Success Stories Awards 2021. They have been recognised for the value that they have consistently achieved for the past 50 years — a success story based on quality, innovation, sustainability and technological leadership. The company has grown over 50% in the last five years —  operating with sites across the world — and now offer more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides.  The prestigious awards, bestowed by the Swiss Biotech Association, celebrate those who have made important and sustainable contributions to the biotech industry in Switzerland. Selected success stories such as Bachem are showcased to illustrate how Sw…

The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies Based on its recent analysis of the global clinical research organization (CRO) market, Frost & Sullivan recognizes leading global CRO Parexel  with the 2021 Global Enabling Technology Leadership Award. Parexel streamlines clients’ clinical development programs, enabling them to navigate market, regulatory, and patient access-related challenges seamlessly. Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market. “Parexel employs a dedicated project t…

UK, 19th July 2021 – The Advanced Therapy Treatment Centre (ATTC) network, London Advanced Therapies (LAT) and the Cell and Gene Therapy Catapult (CGTC), in partnership with Health Education England elearning for healthcare, have developed a new eLearning programme targeted at healthcare and academic professionals to support their learning on both the fundamentals and clinical adoption of advanced therapies. This series of eLearning sessions is designed to give the learner a core understanding of advanced therapies, how they function in the body, and the steps involved in delivering these medicines. The modules take the learner from the basics of cell and gene therapy, through to a more in-depth look at products currently being delivered through both commissioned treatments and clinical tr…

Plan aims to unlock up to £400 million of new private investment and create up to 5,000 new highly-skilled jobs over next decade Stevenage could become one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies Vision for campus developed in partnership with Stevenage Bioscience Catalyst, UK Government and Stevenage Borough Council; GSK to make 33 acres of land available for development at the company’s R&D site in Stevenage GSK has today announced that it has formally started the process of seeking a development partner to transform land within the company’s existing 92-acre Research & Development site in Stevenage into one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies. The vision for the new…